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A retrospective analysis was conducted on data from four open-label, nonrandomised, phase II trials of recombinant interleukin-2
(rIL-2) in patients with metastatic renal cell carcinoma to compare the safety and efficacy of administration by subcutaneous (s.c.) and
continuous intravenous (c.i.v.) infusion (n¼103 s.c. and n¼225 c.i.v.). No statistically significant differences were found between the
cohorts in terms of overall response rate (s.c.: 13.6% vs c.i.v.: 12.4%, P¼0.77), response duration (s.c.: 9.8 months vs c.i.v.: 10.1
months, P¼0.99), and overall survival (P¼0.08). Compared with c.i.v. administration, more patients in the s.c. cohort experienced
stable disease (50.5 vs 29.8%) and fewer underwent disease progression (35.0 vs 43.6%). Subcutaneous administration was associated
with a significantly lower incidence of grade 3 or 4 adverse events (46 vs 76%; Po0.001), and fewer s.c. patients required dose
reductions because of toxicity (20 vs 82%). At the doses and within the schedules tested, this comparative analysis did not detect any
difference in efficacy between s.c. and c.i.v. administration of rIL-2 in terms of overall survival, duration of response and response rate
in patients with metastatic renal cell carcinoma. However, s.c. delivery of rIL-2 was associated with improved tolerability.
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Metastatic renal cell carcinoma (mRCC) carries a poor prognosis.
The response rate to chemotherapy is low and responses are of
short duration (Heinzer et al, 2001). Immunotherapeutic agents
are more successful, and studies with recombinant human
interleukin-2 (rIL-2), the first cytokine registered for this
indication, have demonstrated survival benefits over chemother-
apy for the majority of patients with mRCC (Jones et al, 1993;
Bordin et al, 2000; Fisher et al, 2000; Atzpodien et al, 2002; Lissoni
et al, 2002; Pantuck et al, 2002).
The clinical development of rIL-2 over the past 20 years has
involved investigation of its clinical effects in several regimens
using different routes of administration. In initial studies by
Rosenberg and coworkers at the National Cancer Institute in the
United States, rIL-2 was administered as high-dose intravenous
bolus (i.v.b.) injection (Rosenberg et al, 1985). A typical i.v.b.
regimen comprises the repeated administration of 600000IUkg
 1
of rIL-2 over a period of several days (Taneja et al, 1995). Data
from these i.v.b. studies showed that this regimen has efficacy in
terms of regression in several types of cancer, particularly renal
cell carcinoma and benefits in long-term survival have been
reported (Fisher et al, 2000). However, the risk of severe adverse
events with high-dose bolus rIL-2 treatment necessitates patients
to be hospitalised for drug administration and also limits the
utility of the cytokine to the minority of patients who have good
performance status (Redman and Chang, 2000).
Further research showed that the tolerability of rIL-2 could be
improved without compromising efficacy by delivering intermedi-
ate doses by continuous intravenous infusion (c.i.v.) (West et al,
1987). The introduction of short treatment interruptions in this
regimen improved the toxicity profile compared with i.v.b.
delivery.
To facilitate outpatient treatment, and to enable rIL-2 to be
accessible to more patients, recent studies have focused on further
improving the tolerability of IL-2 regimens. Low-dose subcuta-
neous (s.c.) regimens, for example 9–18 million IU rIL-2 delivered
daily for several weeks, have been investigated in many studies
(Buter et al, 1993; Taneja et al, 1995; Tourani et al, 1996). Findings
from these studies have shown that the s.c. administration of rIL-2
is both efficacious and has an improved side-effect profile over
c.i.v. delivery.
Subcutaneous regimens with rIL-2 alone or in combination with
other agents have been studied intensively in mRCC (Palmer et al,
1993; Tourani et al, 1998; Negrier et al, 2000; Buzio et al, 2001; Gez
et al, 2002). A review of data from several single-agent trials found
no difference in overall response rates and complete response rates
between bolus, c.i.v., and s.c., although s.c. IL-2 showed less
toxicity than i.v. administration (Bukowski, 1997).
In the absence of large controlled trials comparing the clinical
effects of delivering IL-2 by c.i.v. or s.c., we conducted this
retrospective study. Pooled data from four open-label, nonrando-
mised phase II studies were evaluated to assess s.c. and c.i.v. rIL-2
routes of administration in terms of safety and efficacy.
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Study design
This retrospective analysis included data from four open-label,
nonrandomised, multicentre, phase II studies. Two of the studies
used s.c. rIL-2 (study SC1 [Protocol NL-MP-100 {Sleijfer et al,
1992; Buter et al, 1993}]; study SC2 [Protocol EC-MP-101 {Tourani
et al, 1996}]) and two used c.i.v. rIL-2 (study CIV1 [Protocol EC-
L2-008 {von der Maase et al, 1991; Geertsen et al, 1992; Negrier
et al, 1992}] and study CIV2 [Protocol EC-MP-001 {Gore et al,
1994}]).
Patients
The analysis comprised pooled data from 103 patients with mRCC,
included in two rIL-2s.c. studies, and 225 patients with mRCC,
included in two rIL-2 c.i.v. studies. Before study entry, the disease
stage of each patient was determined by full clinical examination.
Patients with histological proven, clinical measurable mRCC, and
with an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0 and 1 for the c.i.v. cohort and 0, 1, and 2 for the s.c.
cohort, were eligible. Histological subtype (e.g. clear cell type,
papillary type) was not prospectively defined as a stratification
factor. All trials excluded patients with brain metastases,
secondary neoplasms, performance status 42, or those who had
been previously treated with rIL-2. Only the s.c. trials permitted
inclusion of patients with concomitant illnesses, for example those
with cardiovascular disease (previous myocardial infarction,
angina pectoris, arrhythmias, cardiac ischaemia, aortic-femoral
bypass, valvular disease), spinal cord lesion, bilateral nephrect-
omy, transient ischaemic attacks, previous cerebrovascular acci-
dent, and porphyria.
Treatments
All patients were treated with commercial rIL-2 (Proleukin
s:
aldesleukin: modified recombinant Human Interleukin-2), pur-
chased from Chiron B.V. (Amsterdam). Continuous intravenous
infusions were administered in oncology wards with close
monitoring during therapy. Subcutaneous injection was adminis-
tered at home or in an outpatient clinic. The dosing regimens used
in these studies are illustrated in Figure 1. To make a comparison
between s.c. and c.i.v. regimens possible, equivalent c.i.v. dosages
(expressed as MIUm
 2) are given in parentheses after the s.c.
dosages. These theoretical equivalents are based on a 68kg patient,
height 173cm and a calculated body surface area of 1.8m
2. Thus, a
s.c. dose of 18MIUday
 1 would be equivalent to a c.i.v. dose of
10MIUm
 2day
 1.
Subcutaneous cohorts In study SC1 (Sleijfer et al, 1992; Buter
et al, 1993), s.c. injections were given for a total of 12 weeks, in
three 4-week or two 6-week treatment cycles, separated by 2- or 3-
week rest periods, respectively (Figure 1A). Patients received
90MIU (theoretically equivalent to 50MIUm
 2week
 1) during
week 1 of each cycle (18MIUday
 1 on days 1–5) and 72MIU
(theoretically equivalent to 40MIUm
 2week
 1) during weeks 2–4
or 2–6 of each cycle (9MIUday
 1 on days 1 and 2 and
18MIUday
 1 on days 3–5). The first 29 patients enroled received
6-week treatment cycles; the remainder received 4-week cycles.
In study SC2 (Tourani et al, 1996), patients received s.c. rIL-2
induction treatment during weeks 1–4 and 6–9. After a 2-week
rest period, responding patients received 4-week maintenance
cycles separated by 2-week rest periods (Figure 1B). Induction
doses of rIL-2 were 90MIU (theoretically equivalent to
50MIUm
 2week
 1) during weeks 1 and 6 (18MIUday
 1 on days
1–5), and 63MIU (theoretically equivalent to 35MIUm
 2week
 1)
during weeks 2–4 and 7–9 (18MIUday
 1 on days 1 and 2, and
9MIUday
 1 on days 3–5). Maintenance doses were 90MIU
(theoretically equivalent to 50MIUm
 2week
 1) during week 1
(18MIUday
 1 on days 1–5), and 63MIU (theoretically equivalent
to 35MIUm
 2week
 1) during weeks 2–4 (18MIUday
 1 on days 1
and 2, and 9MIUday
 1 on days 3–5). Oral acetaminophen (250–
500mg every 4–6h) was administered concomitantly to prevent
pyretic reactions.
Continuous intravenous infusion cohorts For CV1 (Negrier et al,
1989; von der Maase et al, 1991; Geertsen et al, 1992) and CV2
(Gore et al, 1994) the same schedule was used. Treatment consisted
of two induction cycles (each consisting of two, 5-day dosing
periods separated by 2–6 day rest periods) and four maintenance
cycles (5-day dosing periods every 4 weeks). Daily doses of
18MIUm
 2 were administered by 24-h c.i.v. for 5 days (Figure 1C).
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Induction period Repeated
maintenance
Induction cycle (given twice, with 3 weeks’ rest in between)
Maintenance cycle
every 4 weeks  
Figure 1 Dosing regimens used in studies analysed in this retrospective
analysis (A) Study SC1 (12-week subcutaneous treatment using 4- or 6-
week cycles – Protocol NL-MP-100). (B) Study SC2 (subcutaneous
treatment until disease progression/unacceptable toxicity – Protocol EC-
MP-101). (C) Studies CIV1 and CIV2 (continuous intravenous treatment
until disease progression or unacceptable toxicity or up to a maximum of
four maintenance cycles – Protocols EC-L2-008 and EC-MP-001).
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lDose modification was used to control toxicity. Infusion of rIL-2
was interrupted if any of the following complications occurred:
hypotension (grade 3 or 4), significant arrhythmia, suspicion of
myocardial ischaemia, agitation or persistent confusion, elevation
of bilirubin above 5mg 100ml
 1, elevation of serum creatinine
above 4.5mg 100ml
 1, bacterial sepsis, or dyspnoea at rest. The
dose of rIL-2 was reduced by 50% if any of the following
complications occurred during the previous cycle: hypotension
(grade 3 or 4), elevation of bilirubin above 6.0mg 100ml
 1,
elevation of serum creatinine above 5mg 100ml
 1, and neuro-
toxicity (of greater severity than grade 3).
Evaluation of efficacy and safety
Tumour volume was evaluated clinically and radiologically after
the induction period and during maintenance periods of
treatment. Response to therapy was assessed after each treatment
cycle and patients receiving at least one cycle of therapy were
evaluable for response. World Health Organization (WHO) criteria
(Miller et al, 1981) were used to evaluate the tumour response, that
is, complete response (CR), partial response (PR), stable disease
(SD), progressive disease (PD), overall response rate (number of
CRs and PRs), response duration, and for assessing the severity of
adverse events. Adverse events were assessed continually through-
out the study. Overall survival was measured from the initiation of
rIL-2 therapy to the date last known alive or the date of death.
Statistical analyses
All patients included in the original separate analyses of the four
studies were included in this retrospective analysis. The s.c. and
c.i.v. treatment cohorts were compared with respect to pretreat-
ment patient characteristics, including potential prognostic
factors, using the w
2-test for categorical variables and the Wilcoxon
rank-sum test for continuous variables. All patients who received
at least one dose of rIL-2 were entered and included in this
analysis. Overall response to treatment (CRþPR) and overall
incidence of adverse events in individual body systems were
compared using the w
2-test, or Fisher’s exact test when the former
was inappropriate. Percentages and 95% confidence intervals were
calculated for CR, PR, and CRþPR using the Clopper–Pearson
formula for binomial distributions. The Kaplan–Meier product-
limit method was used to estimate the survival distribution and
response duration, which were compared between groups using
the log-rank test. To adjust for imbalances in potential baseline
prognostic factors for mRCC (including: performance status, prior
therapy, prior nephrectomy, number of metastatic sites (1, 2, and
X3) and time from diagnosis to treatment (424 vs p24 months)
(Palmer et al, 1992), and age, a multivariate regression analysis
(Cox proportional hazards model) was used to assess survival. All
statistical analyses were performed using SAS
s version 6.07 or
higher (SAS Institute, Cary, NC, USA). Statistical significance was
assessed at an a ´ level of 0.05 and all reported P-values are two-
sided.
RESULTS
Patients
Baseline characteristics of the patient cohorts treated with s. c. and
c.i.v. rIL-2 are shown in Table 1. There were statistically significant
differences between groups with respect to age, weight, perfor-
mance status, number of metastatic sites, patients who had
received prior hormone therapy, and patients who had received
any type of prior therapy excluding surgery. In general, patients
treated with s.c. rIL-2 were older and heavier, had better
performance status and fewer metastatic sites, and had received
less of at least one type of prior therapy except for surgery than the
cohort who received c.i.v. therapy. These differences were all
statistically significant (all Po0.05).
The groups were well matched with respect to gender; time from
initial diagnosis to start of treatment; time from initial diagnosis to
detection of metastasis; time from detection of metastasis to start
of treatment; and frequency of prior surgery, nephrectomy,
chemotherapy, or radiotherapy.
Treatment
Patients in the s.c. and c.i.v. cohorts spent a similar number of
days on the study (mean 90 vs 88 days, respectively). Both the
mean (692 vs 590MIU) and the median (594 vs 562MIU)
cumulative doses received were higher in the s.c. than in the
c.i.v. cohort (Table 2). A substantially lower proportion of patients
in the s.c. group (20%) required dose reduction because of toxicity
compared with patients receiving c.i.v. treatment (82%) (Table 2).
Efficacy
Of the 103 patients treated with s.c. rIL-2 that were included in the
analysis, 14 (13.6%, 95% CI: 7.6–21.8%) had an overall response,
four (3.9%) had a CR, 10 (9.7%) had a PR, 52 (50.5%) had SD, 36
(35.0%) had disease progression PD, and one (1%) was not
evaluable. Of the 225 patients treated with c.i.v. rIL-2, 28 patients
(12.4%, 95% CI: 8.4–17.5%) had an overall response, seven (3.1%)
had a CR, 21 (9.3%) had a PR, 67 (29.8%) had SD, 98 (43.6%) had
PD and 32 (14.2%) were not evaluable (Table 3). The difference in
overall response between the two treatment groups was not
statistically significant (s.c. 13.6% vs c.i.v. 12.4%; P¼0.77).
Median duration of response was 9.8 months for the s.c.
treatment cohort and 10.1 months for the c.i.v. treatment cohort
(Table 3); the difference between the two treatment groups was not
significant (P¼0.99). Response durations for the four complete
response patients in the s.c. cohort are 27, 64þ,8 6þ, and 93þ
months and for the seven CR patients of the c.i.v. cohort 2, 6, 10,
14þ,4 7þ,7 6þ, and 95þ months.
The results of the univariate analysis of overall survival for the
two rIL-2 treatment groups revealed a significant survival
advantage (P¼0.03) for the s.c. cohort compared with the c.i.v.
cohort. Median survival for the s.c. rIL-2 patients was 13.7 months
(95% CI: 10.6–18.1) vs 9.1 months (95% CI: 8.1–11.3) for c.i.v. rIL-
2. The survival probability over 3 years was higher at each annual
time point in the s.c.-treated group than in the c.i.v. cohort. The
survival probabilities at 1, 3, and 5 years for the s.c. group were 57,
12, and 8%, respectively. For the c.i.v. groups these were 41, 9, and
8%, respectively (Figure 2).
The result on the overall survival was based on a retrospective
analysis on data of nonrandomised phase II studies. Therefore, a
multivariate analysis was done. After correcting for imbalances in
baseline characteristics to be potentially prognostic for mRCC,
known at the time these studies were done (performance status,
number of metastatic sites, time from diagnosis to treatment
(Palmer et al, 1992), and for significant different baseline
characteristics between the two treatment cohorts (age, weight,
prior therapy)) the s.c. and c.i.v. regimens were found not to be
significant different in terms of overall survival (P¼0.08).
Safety
The overall incidence of adverse events was similar in the s.c. and
c.i.v. cohorts (P¼0.66) (Table 4). However, comparison of the
body systems affected by all adverse events, regardless of their
severity, showed that the s.c. and c.i.v. administration routes were
associated with significantly different safety profiles (Table 4).
Subcutaneous delivery was more frequently associated with
adverse events affecting the endocrine system (Po0.001). Admin-
istration by c.i.v. was more frequently associated with adverse
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rIL-2 regimen
Parameter s.c. (n¼103) c.i.v. (n¼225) All (n¼328) P-value
Age (years) 0.02
Median (range) 59.0 (21–84) 56.0 (20–80) 57.0 (20–84)
Sex, N (%) ns
Female 34 (33) 69 (31) 103 (31)
Male 69 (67) 156 (69) 225 (69)
Weight (kg) (n¼95) (n¼222) (n¼317) 0.03
Median (range) 74.0 (46–110) 71.0 (41.5–107) 71.0 (41.5–110)
ECOG performance status, n (%) o0.001
0 58 (56) 94 (42) 152 (46)
1 38 (37) 131 (58) 169 (52)
2 7 (7) 0 (0) 7 (2)
Time from diagnosis to start of treatment, n (%) ns
p24 months 81 (79) 179 (80) 260 (79)
424 months 22 (21) 46 (20) 68 (21)
Time from diagnosis to detection of metastasis, n (%) ns
p24 months 83 (81) 184 (82) 267 (81)
424 months 17 (17) 37 (16) 54 (16)
Unknown 3 (3) 4 (2) 7 (2)
Time from detection of metastasis to start of treatment, n (%) ns
p24 months 94 (91) 214 (95) 308 (94)
424 months 6 (6) 7 (3) 13 (4)
Unknown 3 (3) 4 (2) 7 (2)
Prior therapy, n (%)
At least one type of prior therapy (excl. surgery) 22 (21) 82 (36) 104 (32) o 0.01
Surgery 83 (81) 184 (82) 267 (81) ns
Nephrectomy 87 (76) 173 (77) 251 (77) ns
Chemotherapy 7 (7) 11 (5) 18 (5) ns
Radiotherapy 15 (15) 40 (18) 55 (17) ns
Hormontherapy 0 (0) 43 (19) 43 (13) o0.001
Immunotherapy 7 (7) 16 (7) 23 (7) ns
Metastatic disease at nephrectomy (n¼74) (n¼171) (n¼245) ns
Yes 10 (14) 22 (13) 32(13)
No. of metastatic sites (n¼101) (n¼225) (n¼326) 0.04
1 41 (41) 75 (33) 116 (36)
2 43 (43) 82 (36) 125 (38)
X3 17 (17) 68 (30) 85 (26)
s.c.¼subcutaneous – Study SC1 (Protocol NL-MP-100 [Sleijfer et al, 1992; Buter et al, 1993]) and Study SC2 (Protocol EC–MP–101 [Tourani et al, 1996]). c.i.v.¼continuous
intravenous infusion – Study CV1 (Protocol EC-L2–008 [von der Maase et al, 1991; Geertsen et al, 1992; Negrier et al, 1992]) and Study CV2 (Protocol EC-MP-001 [Gore et al,
1994]). ECOG¼Eastern Cooperative Oncology Group.
Table 2 Summary of rIL-2 doses received and treatment duration
rIL-2 regimen
Parameter s.c. (n¼103) c.i.v. (n¼225)
Patients with dose reduction 21 (20%) 184 (82%)
Mean number of days in study 90 88
Median number of days in study 70 73
Range of days in study 14–385 1–268
Mean cumulative dose (MIU) 692 590
Median cumulative dose (MIU) 594 562
Dose range (135–2232) (60–1710)
s.c.¼subcutaneous; c.i.v.¼continuous intravenous infusion.
Table 3 Summary of clinical responses
rIL-2 regimen
Parameter s.c. (n¼103) n (%) c.i.v. (n¼225) n (%)
CR 4 (3.9) 7 (3.1)
PR 10 (9.7) 21 (9.3)
CR+PR (95% CI) 14 (13.6, 7.6–21.8) 28 (12.4, 8.4–17.5)
SD 52 (50.5) 67 (29.8)
PD 36 (35.0) 98 (43.6)
NE 1 (1.0) 32 (14.2)
Median response duration
(months, range)
9.8 (4–93+)
a 10.1 (1–95+))
a
s.c.¼subcutaneous; c.i.v.¼continuous intravenous infusion.
as.c.: n¼14, c.i.v.: n¼28
for these calculations; SD¼stable disease; CR¼complete response; PR¼partial
response; PD¼progressive disease; NE¼not evaluable.
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levents affecting the cardiovascular, haemic/lymphatic, nervous,
and urogenital systems (all Po0.001).
Severe adverse events (grade 3 or 4) occurred more frequently in
patients who received the c.i.v. regimen than in those treated with
s.c. rIL-2 (76 vs 46%; Po0.001) (Table 5). More patients in the
c.i.v. group, compared with those in the s.c. cohort, experienced
severe adverse events of the cardiovascular, respiratory, urogenital
systems (all Po0.001), and metabolic/nutritional system
(P¼0.002). Individual, severe adverse events that were more
commonly reported in the c.i.v. group vs the s.c. cohort included
fever (23 vs 17%), hypotension (36 vs 2%), anaemia (9 vs 4%),
oliguria (6 vs 0%), and increased alkaline phosphatase levels (14 vs
0%).
Injection site reactions were, as expected, only associated with
s.c. administration of rIL-2, with 50% of patients in this group
reporting this adverse event. The majority (495%) of injection site
reaction events were graded as mild (grade 1) and usually
diminished within 1 week.
Dose modification of rIL-2 was not required by the majority of
s.c. patients (80%) but was frequently necessary in patients
receiving c.i.v. rIL-2 (82%). Treatment delays were also less
frequent in patients in the s.c. cohort than in patients in the c.i.v.
group (4 vs 20%) (Table 6).
DISCUSSION
In this study, we have retrospectively analysed the efficacy and
safety of s. c. and c.i.v. routes of administration of rIL-2 in mRCC
patients.
The analysis did not detect any significant differences between
either method of administration with respect to overall response,
median response duration, and overall survival, after correcting for
imbalances in baseline prognostic factors (performance status,
number of metastatic sites, time from diagnosis to treatment) and
baseline characteristics (age, weight, prior therapy). However, a
greater proportion of patients in the s.c. cohort experienced SD
compared to patients in the c.i.v. group (35.0 vs 43.6%
respectively). Long-lasting complete responses (45 years) were
found in both cohorts.
Nowadays, histological subtype is a known prognostic factor for
renal cell carcinoma. The majority of renal cell carcinoma is of the
c.i.v. IL2 (N = 225)
s.c. IL2 (N = 103)
132 120 108 96 84 72 60 48 36 24 12 0
0
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Figure 2 Overall survival in patients with metastatic renal cell carcinoma
treated with subcutaneous (s.c.) or continuously infused (c.i.v.) rIL-2;
retrospectively pooled data from open-label, nonrandomised trials.
Table 4 Summary of all adverse events, including abnormalities in
laboratory values, by body system
rIL-2 regimen
Body system
s.c.
(n¼103) %
c.i.v.
(n¼225) % P-value
Any adverse event 103 100 222 99 0.66
Body as a whole 99 96 211 94 0.39
Cardiovascular system 19 18 174 77 o0.001
Digestive system 86 83 156 69 0.007
Disease related 0 0 1 o1 1.0
Endocrine system 13 13 2 1 o0.001
Eye 2 2 16 7 0.068
Haemic and lymphatic system 63 61 182 81 o0.001
Metabolic and nutritional disorders 77 75 198 88 0.002
Musculoskeletal system 3 3 6 3 1.0
Mucosa 1 1 23 10 0.002
Nervous system 11 11 67 30 o0.001
Not specified 0 0 1 o1 1.0
Respiratory system 16 16 67 30 0.006
Skin and appendages 41 40 133 59 0.001
Special senses 1 1 0 0 0.31
Urogenital system 4 4 73 32 o0.001
Injection site 52 50 1 o1 o0.001
s.c.¼subcutaneous; c.i.v.¼continuous intravenous infusion.
Table 5 Summary of severe (grade 3 or 4) adverse events, including
laboratory abnormalities, by body system
rIL-2 regimen
Body system
s.c.
(n¼103) %
c.i.v.
(n¼225) % P-value
Any adverse event 47 46 171 76 o0.001
Body as a whole 26 25 73 32 0.19
Cardiovascular system 3 3 78 39 o0.001
Digestive system 9 9 30 13 0.23
Endocrine system 1 1 0 0 0.31
Eye 0 0 1 o1 1.0
Haemic and lymphatic system 10 10 22 10 0.98
Metabolic and nutritional disorders 10 10 54 24 0.002
Musculoskeletal system 1 1 2 1 1.0
Nervous system 1 1 28 12 o0.001
Not specified 0 0 1 o1 1.0
Respiratory system 0 0 31 14 o0.001
Skin and appendages 4 4 17 8 0.21
Urogenital system 3 3 24 11 0.018
Injection site 5 5 0 0 1.0
s.c.¼subcutaneous; c.i.v.¼continuous intravenous infusion.
Table 6 Summary of dose modifications and treatment delays
rIL-2 regimen
s.c.
(n¼103)
c.i.v.
(n¼225)
Dose modifications (N/patient)
Mean 0.3 6.5
Median 0.0 4.0
Range 0–4 0–49
Dose not modified (N [%]) 82 (80%) 41 (18%)
Treatment delays (N [%])
Yes 4 (4%) 45 (20%)
No 99 (96%) 180 (80%)
Unknown 0 18
s.c.¼subcutaneous; c.i.v.¼continuous intravenous infusion.
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lclear cell carcinoma type (75%). Patients with this subtype benefit
most from IL-2 therapy (Wu et al, 1998). The outcome of our
retrospective analysis could have been influenced by the histolo-
gical subtypes of the patients. At the time these studies were
conducted, histological subtype was not a known prognostic factor
for clinical outcome of renal cell carcinoma patients, and therefore
no distinction was made prospectively on this parameter. Because
of the limitations of our database it is not possible to look back at
these specific subtypes. However, clinical trials should include
better pathologic stratification at enrolment of RCC patients.
Furthermore, the analysis shows that s.c. administration is
associated with an improved tolerability profile, compared with
the c.i.v. route of administration. Patients in the s.c. group
experienced significantly fewer severe side effects than those in the
c.i.v. cohort (46 vs 76%, Po0.001). Patients in the s.c. cohort also
needed fewer toxicity-related dose reductions of rIL-2, compared
with those in the c.i.v. group (20 vs 82%). This outcome is recently
confirmed by Yang et al (2003), who compared response rates and
overall survival of patients with metastatic renal cell carcinoma in
a randomised study receiving either high-dose or one of two low-
dose IL-2 regimens (high-dose bolus i.v., low-dose bolus i.v., and
s.c. resp.). With a median follow-up of 7.4 years, long-term
survival was 21% for all study patients and there were no
significant differences in overall survival between the three arms,
although the response rate of bolus IL-2 was higher that that of the
s.c. IL-2 regimen. However, the safety profile was markedly
improved with the s.c. treatment with respect to both i.v. regimens.
However, a notable exception is the significant higher incidence
of adverse events concerning the endocrine system found in
patients treated by the s.c. route of administration. It is known that
reversible thyroid dysfunction occurs in up to 60% of metastatic
cancer patients treated with immunotherapy consisting of IL-2
alone or in combination with interferon-a or lymphocyte-activated
killer cells. It has been associated with favourable tumour response
(Weijl et al, 1993; Franzke et al, 1999). The higher percentage of SD
found in patients from the s.c. cohort (50.5 and 29.8% for s.c. and
c.i.v. rIL-2 treatment, respectively) may be somehow related by the
higher incidence of thyroid dysfunction in this treatment group. It
has been speculated that the cytokines enhance the immune
response to certain autoantigens as well as to antigens present on
tumour cells, or that the immune responses to thyroid tissue and
tumour tissue are similarly regulated (Franzke et al, 1999).
Our findings have to be considered within the limitations of our
analysis. We have compared data from two different cohorts of
patients from four different phase II studies, which were
conducted at different centres. Although we have adjusted in our
statistical analysis for imbalances in prognostic factors known at
the time these studies were conducted, they may have biased the
results. This may also be valid for other prognostic factors
identified afterwards. However, our data are consistent with other
studies, suggesting that s.c. administration has similar efficacy as
c.i.v. treatment but is associated with milder side effects
(Bukowski, 1997).
The improved tolerability of s.c. delivery of rIL-2 may be
explained by factors such as the mechanism of action and
distribution of rIL-2 within the body. Low doses of rIL-2, delivered
by s.c., results in picomolar concentrations of circulating rIL-2 that
specifically stimulates production of natural killer cells. In
contrast, the higher doses used in c.i.v. administration stimulate
expansion of a broad range of immune cells, which are suspected
to cause severe adverse events that may occur during treatment
(Fehniger et al, 2002). Furthermore, s.c. administration of rIL-2
provides a lower and more consistent level of systemic drug
exposure than delivery by c.i.v. This also may contribute to the
favourable tolerability profile observed with this mode of
administration (Konrad et al, 1990; Leahy et al, 1992; Yang and
Rosenberg, 1997).
The improved tolerability of s.c. rIL-2 supports its administra-
tion in the outpatient setting. Compared to c.i.v. delivery in
hospital, treatment with s.c. rIL-2 at home or in the community
may lead to an improvement in patients’ quality of life and reduce
healthcare management costs. In addition, the improved toler-
ability of s.c. delivery may allow rIL-2 to have clinical utility in a
wider variety of patients, including those with poor performance
and patients with concomitant systemic disease.
In conclusion, this retrospective analysis did not detect any
difference in efficacy between s.c. and c.i.v. administration of rIL-2
in terms of overall survival, duration of response and response rate
in patients with mRCC. However, s.c. delivery of rIL-2 has
improved tolerability compared with c.i.v. administration. These
data are consistent with the growing body of evidence that shows
s.c. IL-2 to be effective, well tolerated, and suitable for use as an
outpatient treatment (Bukowski, 1997). In the absence of results
from large controlled trials, it is hoped that data from our analysis
will provide additional evidence to assist clinicians’ use of rIL-2 in
mRCC in their current clinical practice. Other factors, that may
well help maximise the effectiveness of rIL-2 therapy, include the
identification of new prognostic factors (van Herpen and de
Mulder, 2002), the identification of biological markers of
immunotherapies’ efficacy and combination with other agents
(e.g. vaccines, dendritic cells) (Malaguarnera et al, 2001). To
optimise fully the clinical application of rIL-2, these and other
questions need to be investigated so that the most appropriate rIL-
2 dose and scheduling regimen can be identified.
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